Last updated on July 2019

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])


Brief description of study

This is a study of pembrolizumab (MK-3475, KEYTRUDA) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.

Clinical Study Identifier: NCT03517449

Find a site near you

Start Over

Holy Name Medical Center

Teaneck, NJ United States
  Connect »

University of Rochester

Rochester, NY United States
  Connect »

Stephenson Cancer Center

Oklahoma City, OK United States
  Connect »

Sanford Gynecology Oncology

Sioux Falls, SD United States
  Connect »

UT West Cancer Center

Germantown, TN United States
  Connect »

Hospital Aleman

Buenos Aires, Argentina
  Connect »

Sanatorio Guemes

Buenos Aires, Argentina
  Connect »

Flinders Medical Centre

Bedford Park, Australia
  Connect »

St John of God

Subiaco, Australia
  Connect »

Oncomedica S.A.

Monteria, Colombia
  Connect »

National Cancer Center

Goyang-si, Korea, Republic of
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Leningrad Regional Oncology Center

Saint-Petersburg, Russian Federation
  Connect »

Addenbrookes Hospital

Cambridge, United Kingdom
  Connect »

Western General Hospital

Edinburgh, United Kingdom
  Connect »

Utah Cancer Specialists

Salt Lake City, UT United States
  Connect »